T

    Trevi Therapeutics Inc (TRVI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.60
    -0.19 (-1.13%)

    Market Cap: $2.37B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(22/30)
    Avg Surprise
    -77.19%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.18 - $-0.11
    10 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.12+8.3%
    60d ago$-0.13+3.1%
    30d ago$-0.13+3.1%
    7d ago$-0.13+3.0%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.16
    Range$-0.26 - $-0.02
    10 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.16---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 6
    		$-0.11$-0.11+0.00%Beat-22.2%
    Mar 26
    Reported May 5
    		$-0.09$-0.07-28.57%Miss+0.0%
    Dec 25
    Reported Mar 17
    		$-0.06$-0.10+39.09%Beat+45.5%
    Sep 25
    Reported Nov 13
    		$-0.08$-0.10+20.00%Beat+38.5%
    Jun 25
    Reported Aug 7
    		$-0.09$-0.10+10.00%Beat+25.0%
    Mar 25
    Reported May 8
    		$-0.09$-0.12+25.00%Beat+18.2%
    Dec 24
    Reported Mar 18
    		$-0.11$-0.12+6.06%Beat-37.5%
    Sep 24
    Reported Nov 6
    		$-0.13$-0.11-18.18%Miss-62.5%
    Jun 24
    Reported Aug 8
    		$-0.12$-0.11-9.09%Miss-71.4%
    Mar 24
    Reported May 7
    		$-0.11$-0.09-22.22%Miss-83.3%
    Dec 23
    Reported Mar 20
    		$-0.08$-0.09+11.11%Beat-33.3%
    Sep 23
    Reported Nov 9
    		$-0.08$-0.09+11.11%Beat+33.3%
    Jun 23
    Reported Aug 10
    		$-0.07$-0.09+22.22%Beat+50.0%
    Mar 23
    Reported May 11
    		$-0.06$-0.07+14.29%Beat+75.0%
    Dec 22
    Reported Mar 16
    		$-0.06$-0.10+40.00%Beat+78.6%
    Sep 22
    Reported Nov 10
    		$-0.12$-0.13+7.69%Beat+64.7%
    Jun 22
    Reported Aug 11
    		$-0.14$-0.18+22.22%Beat+71.4%
    Mar 22
    Reported May 12
    		$-0.24$-0.29+17.24%Beat+44.2%
    Dec 21
    Reported Mar 17
    		$-0.28$-0.30+6.67%Beat+45.1%
    Sep 21
    Reported Nov 10
    		$-0.34$-0.39+12.82%Beat+17.1%
    Jun 21
    Reported Aug 12
    		$-0.49$-0.46-6.52%Miss-19.5%
    Mar 21
    Reported May 13
    		$-0.43$-0.52+17.31%Beat+10.4%
    Dec 20
    Reported Mar 25
    		$-0.51$-0.44-15.91%Miss-37.8%
    Sep 20
    Reported Nov 12
    		$-0.41$-0.51+19.61%Beat+0.0%
    Jun 20
    Reported Aug 13
    		$-0.41$-0.48+14.58%Beat+0.0%
    Mar 20
    Reported May 7
    		$-0.48$-0.44-9.09%Miss+96.5%
    Dec 19
    Reported Mar 16
    		$-0.37$-0.51+27.45%Beat-
    Sep 19
    Reported Nov 14
    		$-0.41$-0.47+12.77%Beat+30.5%
    Jun 19
    Reported Aug 12
    		$-0.41$-0.41+0.00%Beat-
    Mar 19
    Reported May 8
    		$-13.85$-0.52-2563.46%Miss-
    Dec 18
    Reported Feb 27
    		$0.00$0.00N/ABeat-
    Sep 18
    Reported Dec 21
    		$-0.59$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-48.82EV/EBITDA-4.92x
    Price/FCF-39.18xFCF Yield-2.55%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-19.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio37.28xQuick Ratio37.28x
    Trading Statistics
    Beta1.07Avg Volume1.57M
    52-Week High$20.2252-Week Low$6.93

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.92
    SMA 20$18.10
    SMA 50$18.02
    SMA 200$13.92
    EMA 10$17.65
    EMA 20$17.86
    EMA 50$17.45
    EMA 200$14.22

    MACD

    Line: -0.14Signal: 0.08Hist: -0.22

    ADX

    ADX: 23.6+DI: 17.3-DI: 26.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down100.0
    PSAR$19.85

    Bollinger Bands

    Upper Band$19.29
    Lower Band$16.90
    %B Position1320%(Upper)
    Band Width-0.13

    RSI (14-Day)

    Neutral
    36.5

    Momentum Oscillators

    Stoch %K19.1
    Stoch %D26.0
    Williams %R-83.9
    ROC (10d)-10.2%
    Momentum-1.88
    CCI (20d)-273.4
    MFI (14d)54.7

    Volatility Measures

    ATR (14d)$0.88(5.3%)
    StdDev (20d)0.60
    Hist Vol37.2%(Moderate)

    Volume Flow

    VWAP$16.47
    OBV137.8M
    AD Line13.7M
    CMF (20d)0.042

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio1.2x
    VWMA (20d)$18.12

    Pivot Points

    R3$19.18
    R2$18.63
    R1$17.71
    Pivot Point$17.17
    S1$16.25
    S2$15.70
    S3$14.78

    Advanced Oscillators

    TSI-4.83
    Ultimate Osc49.4
    KST-7.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$146,000$0$0$0$176,000$0
    Cost of Revenue$0$0$31,000$0$0$0$38,000$0$0$0$35,000$0
    Gross Profit$0$0$-31,000$0$0$0$-38,000$0$0$0$-35,000$0
    Operating Expenses$20.51M$14.91M$10.22M$13.92M$13.72M$11.47M$12.24M$14.09M$13.29M$11.91M$8.93M$9.04M
    R&D$15.15M$9.94M$6.19M$10.09M$9.39M$7.81M$9.33M$11.22M$10.02M$8.80M$6.52M$6.32M
    SG&A$5.36M$4.97M$4.03M$3.83M$4.33M$3.66M$2.91M$2.86M$3.27M$3.10M$2.42M$2.72M
    Operating Income$-20,509,000$-14,912,000$-10,220,000$-13,916,000$-13,722,000$-11,470,000$-12,242,000$-14,087,000$-13,289,000$-11,906,000$-8,933,000$-9,045,000
    Interest Income$2.70M$1.70M$1.90M$2.10M$1.41M$1.13M$843,000$826,000$935,000$998,000$1.14M$1.18M
    Interest Expense$0$0$0$0$0$0$1,000$1,000$1,000$1,000$4,000$3,000
    Income Before Tax$-17,816,000$-13,212,000$-8,333,000$-11,817,000$-12,322,000$-10,351,000$-11,398,000$-13,273,000$-12,360,000$-10,910,000$-7,803,000$-7,711,000
    Income Tax Expense$-19,000$-20,000$-17,000$-15,000$-21,000$-11,000$17,000$-31,000$-8,000$-8,000$18,000$-13,000
    Net Income$-17,797,000$-13,192,000$-8,316,000$-11,802,000$-12,301,000$-10,340,000$-11,415,000$-13,242,000$-12,352,000$-10,902,000$-7,821,000$-7,698,000
    EBITDA$-20,995,000$-15,305,000$-10,767,000$-14,178,000$-14,074,000$-11,834,000$-12,499,000$-14,415,000$-13,592,000$-12,253,000$-9,252,000$-9,468,000
    EBIT$-20,512,000$-14,908,000$-10,236,000$-13,918,000$-13,729,000$-11,476,000$-12,240,000$-14,098,000$-13,294,000$-11,907,000$-8,936,000$-8,891,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TRVI

    News

    Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

    Trevi Therapeutics announced that two abstracts have been accepted for presentation at the European Respiratory Society (ERS) Congress 2026. The presentations will detail quality-of-life outcomes from the Phase 2b CORAL trial for IPF-related chronic cough and the Phase 2a RIVER trial for refractory chronic cough, both assessing nalbuphine ER. This highlights Trevi's progress in developing Haduvio (oral nalbuphine ER) for chronic cough conditions with high unmet medical needs.

    GlobeNewswire•8/26/26•
    Bullish

    Trevi Therapeutics (TRVI) Institutional Ownership 2026 $TRVI

    This article details the institutional ownership of Trevi Therapeutics (TRVI) as of August 2026. It provides data on the percentage of stock owned by institutions, the number of buyers and sellers, and total inflows and outflows over the past 12 months. A comprehensive table lists major shareholders, their shares held, market value, and quarterly changes.

    MarketBeat•8/20/26•
    Neutral

    Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI)

    Trevi Therapeutics is positioned to leverage its drug Haduvio to target IPF-related chronic cough, with plans to expand into non-IPF ILD and refractory chronic cough. The company's strategy focuses on concentrated pulmonology networks, enabling efficient market entry and growth. With positive Phase II data, ongoing pivotal trials, and reduced competition, TRVI presents a compelling risk/reward profile.

    Seeking Alpha•8/20/26•
    Bullish

    Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI

    Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from analysts, with a target price of $27.08, despite recent mixed analyst actions including a downgrade to "Sell" from one firm.

    MarketBeat•8/15/26•
    Bullish

    Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)?

    Trevi Therapeutics reported wider net losses and a higher loss per share in Q2 2026, alongside filing a US$149.2 million shelf registration for 8,000,000 common shares. These developments introduce greater funding risk and potential dilution, which may challenge optimistic analyst forecasts for the company's Haduvio program. While Haduvio's trial results remain a key driver, investors should consider the implications of increased financing needs on future share count and earnings per share.

    Simply Wall Street•8/14/26•
    Somewhat-Bearish

    Frequently Asked Questions About TRVI

    Does TRVI pay dividends?
    Trevi Therapeutics Inc (TRVI) does not currently pay a regular dividend.
    What is TRVI's market cap?
    Trevi Therapeutics Inc (TRVI) has a market capitalization of $2.37B with a current stock price of $16.60.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In